Patient characteristics from the Amsterdam Reade cohort and the Northern Sweden cohort
| Amsterdam Reade cohort | Northern Sweden cohort | ||||
|---|---|---|---|---|---|
| Non-converting individuals at risk | Converting individuals at risk | Population-based controls | Preclinical individuals | RA patients | |
| Individuals (n) | 71 | 44 | 45 | 25 | 23 |
| Females (n), (%) | 55 (77) | 38 (86) | 45 (100) | 25 (100) | 23 (100) |
| Median age at sample collection in years (IQR) | 49 (41–56) | 46 (39–55) | 61 (54–64) | 60 (54–62) | 62 (57–65) |
| ACPA positive (n), (%) | 44 (62) | 40 (91) | 0 (0) | 9 (36) | 15 (65) |
| RF positive (n), (%) | 31 (44) | 26 (59) | 2 (6)* | 8 (32) | 18 (78) |
| ACPA and RF Positive (n), (%) | 12 (17) | 23 (52) | 0 (0) | 6 (24) | 15 (65) |
| Shared epitope (n), (%) | 30 (46)† | 26 (67)‡ | ND | ND | ND |
| ESR (IQR) | 13.5 (5.0–20.0) | 9.5 (5.5–19.25)§ | ND | ND | 25 (14.0–41.5) |
| CRP (IQR) | 2.00 (0.86–4.95)¶ | 2.68 (0.97–4.75) | ND | ND | 10.5 (10.0–20.5) |
| NSAID use (n), (%) | 18 (25) | 14 (32) | ND | ND | 7 (30) |
| DMARD use (n), (%) | 0 (0) | 0 (0) | ND | ND | 8 (35) |
| Corticosteroids (≤7.5 mg) use (n), (%) | 0 (0) | 0 (0) | ND | ND | 8 (35) |
| Median follow-up time in months (IQR) | 23 (12–35) | 20 (12–26) | NA | NA | 132 (108–144) |
| Median time to conversion in months (IQR) | NA | 8 (5–13) | NA | NA | NA |
| 2010 ACR/EULAR criteria (n), (RA/UA) | NA | 40/4 | NA | NA | NA |
| 1987 ACR criteria (n), (RA/UA) | NA | 18/26 | NA | NA | 23/0 |
*Available for 34 out of 45 patients.
†Available for 65 out of 71 patients.
‡Available for 39 out of 44 patients.
§Available for 38 out of 44 patients.
¶Available for 69 out of 71 patients.
ACPA, anticitrullinated peptide antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NA, not applicable; ND, not determined; NSAID, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; UA, undifferentiated arthritis.